Mirabegron Teva

Mirabegron, the active ingredient in Mirabegron Teva, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral use. It treats overactive bladder symptoms such as urgency, frequency, and urge incontinence in adult patients.

GNH USA supplies Mirabegron Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets. Its global distribution network ensures timely delivery and compliance with local regulatory requirements.

Mirabegron is indicated for conditions within the overactive bladder disease spectrum, improving bladder storage function.

- Overactive bladder: increases bladder capacity and reduces urgency episodes. - Urinary urgency: lessens the frequency of sudden urges to void. - Urinary frequency: decreases the number of daytime voids. - Urge urinary incontinence: reduces episodes of involuntary leakage.

Mirabegron may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Hypertension: increase in blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Headache: transient head pain of varying intensity. - Constipation: reduced bowel movements or hard stools.

Serious or Rare Side Effects: - Urinary retention: difficulty emptying the bladder requiring medical attention. - Severe hypertension: markedly elevated blood pressure that may need intervention. - Tachycardia: rapid heart rate potentially symptomatic. - Angioedema: swelling of face, lips, tongue or airway demanding urgent care.

Before initiating Mirabegron therapy, clinicians should evaluate several safety considerations.

- Monitor blood pressure: check baseline and periodic measurements. - Assess renal function: adjust use in patients with severe impairment. - Avoid use in uncontrolled hypertension: risk of further blood pressure rise. - Use caution in the elderly: increased susceptibility to adverse effects. - Review concomitant medications: consider potential drug interactions. - Store at room temperature: keep in the original container, protect from moisture.

Mirabegron can affect the pharmacokinetics of other medicines, requiring attention to interaction risk levels.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors: may increase mirabegron plasma concentrations. - Strong CYP3A4 inhibitors: can raise exposure and heighten side‑effect risk. - Anticholinergic agents: may diminish therapeutic benefit on bladder symptoms.

Moderate Interactions (Monitor Closely): - Diuretics: may potentiate hypertension when combined. - Antihypertensives: mirabegron may attenuate their blood‑pressure‑lowering effect. - Warfarin: monitor INR as mirabegron can alter anticoagulant activity.